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This is part of a series of occasional articles on common problems in primary care. The BMJ 
welcomes contributions from GPs. 
Box start 
What you need to know 
When hyperthyroidism is confirmed, offer referral for endocrinology assessment, after arranging 
initial investigations including thyroid auto-antibodies 
While endocrine review is pending, offer beta blockers to manage adrenergic symptoms; if 
symptomatic and a non-transient cause is likely, start anti-thyroid drugs (ATDs) and recheck 
thyroid function tests 2-4 weeks later 
Avoid pregnancy until normal thyroid function is restored 
Box end 
A 36 year old woman presents to her GP with a six week history of palpitations, agitation, and 
unintentional weight loss of 12 kg over four months. She initially attributed her symptoms to stress 
relating to work pressures and a recent house move. Blood tests are arranged, which show a fully 
suppressed thyroid stimulating hormone (TSH) of <0.01 mU/L and free thyroxine of 86.1 pmol/L. 
Hyperthyroidism describes excess hormone production from the thyroid gland. Thyrotoxicosis 
arises from excess circulating thyroid hormones due to any cause, including hyperthyroidism (fig 1). 
Hyperthyroidism is a biochemical diagnosis. Establishing the underlying aetiology is essential to 
determine the appropriate management. 
Overall population prevalence is 0.3%-2% and annual incidence is 0.1-4 per 1000.1 2 Graves’ disease 
accounts for up to 80% of cases, with peak incidence at age 30-50 (F:M 10:1). In older adults, toxic 
adenoma/multinodular goitre are responsible for a higher proportion of cases.  
This article describes the first reasonable steps in diagnosing and managing hyperthyroidism for 
non-specialists in primary care. 
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Fig 1 Causes of thyrotoxicosis. Common causes are listed in bold, † non-nucleoside reverse 
transciptase inhibitors ‡ protease inhibitors 
What you should cover 
- Establish the severity and duration of thyrotoxic symptoms. If patient has evidence of 
possible thyroid storm (box 1) this requires emergency referral.  
- Explain that the condition is likely to be reversible with treatment. Box 2 covers useful key 
points for explanation to patients. 
- Try to establish the likely cause. It is clinically relevant to distinguish between: 
1) Transient causes of thyrotoxicosis, such as thyroiditis, which typically require no specific 
treatment; 
2) Non-transient causes, principally Graves’ disease and toxic adenoma/multinodular goitre; 
and  
3) Exogenous causes, due to the drugs listed in figure 1. 
Fever and neck pain/tenderness suggest thyroiditis. Personal/family history of autoimmune 
disease increases the likelihood of Graves’ disease. Smoking increases the risk of Graves’ and 
thyroid eye disease. Exogenous causes of thyrotoxicosis include recent iodinated radiological 
contrast, intentional or unintentional thyroid hormone use (e.g. as a component of weight loss 
supplements), and over-the-counter supplements that contain iodine (e.g. kelp). Increasingly, new 
pharmacological agents, including antiretrovirals (non-nucleoside reverse-transcriptase inhibitors, 
protease inhibitors) and cancer immunotherapy drugs are seen to precipitate thyroiditis. Pregnancy 
within the last six months suggests postpartum thyroiditis, a common and self-limiting condition for 
which anti-thyroid drugs are not indicated. Risk of relapse of Graves’ disease is also higher 
postpartum. 
- Discuss plans for and risks associated with pregnancy in women of childbearing age. Active 
thyrotoxicosis confers a higher risk of miscarriage, pre-eclampsia, intrauterine growth 
restriction, preterm labour, and stillbirth. Pregnancy also influences treatment choice (see 
below). 
- If concerns about thyroid cancer are raised, it is generally appropriate to reassure the patient 
that malignancy is exceedingly uncommon in functional thyroid nodules, i.e. those that 
release excess thyroid hormone to cause thyrotoxicosis.   
Box start 
Box 1 Complications of thyrotoxicosis 
• Atrial fibrillation 
• Cardiac failure 
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• Thyroid eye disease in Graves’ disease 
• Osteoporosis 
• Psychiatric features: mood disorders, anxiety, rarely frank psychosis 
• Thyrotoxic crisis (thyroid storm): tachycardia, fever, atrial fibrillation, vomiting, dehydration, 
jaundice, agitation, delirium, coma 
• Adverse pregnancy outcomes: pre-eclampsia, intrauterine growth restriction, miscarriage, 




Box 2 What to say to patients 
What is hyperthyroidism? 
The thyroid is a hormone-producing gland in the neck that regulates metabolism. Excess production 
or release of thyroid hormones, “hyperthyroidism,” produces a state of overactive metabolism that 
can lead to symptoms including weight loss, tremor, sweating, insomnia, and restlessness. Symptoms 
vary considerably from person to person, and in some cases, there may be no symptoms at all. The 
diagnosis is made by blood tests to measure levels of circulating thyroid hormones. 
What causes hyperthyroidism? 
There are many possible causes of hyperthyroidism. The most common are: 
- Graves’ disease, an autoimmune condition which occurs when the immune system reacts 
inappropriately to produce antibodies that overstimulate the thyroid gland; 
- Enlarged nodules within the thyroid gland, which overproduce thyroid hormones; 
- Thyroiditis, or inflammation of the gland, which causes pre-formed hormones to leak into the 
blood; this doesn’t cause hormone overproduction and is therefore generally temporary. 
What is the recommended treatment? 
Initial treatment with drugs known as “beta blockers” is given to relieve symptoms and to prevent 
excess thyroid hormones from affecting the heart. Medication to inhibit thyroid hormone production 
may also be started. Referral to an endocrinologist is required to determine the need for further tests 
to establish the cause, and to make an ongoing treatment plan. 
Box end 
What you should do 
[QtoA: are there any guidelines/evidence references for these below?] 
Assessment 
Assess for complications of thyrotoxicosis (box 1). Assess and document pulse, blood pressure, and 
temperature. Assess for atrial fibrillation, signs of fluid overload or heart failure, goitre, clinically 
evident thyroid nodules, and stigmata of Graves’ disease, including orbitopathy.  
Repeat thyroid function tests (including fT4 and free triiodothyronine, fT3, if initial fT4 was 
normal) along with thyroid stimulating receptor antibodies (TRAbs).3 TRAbs are 98% sensitive and 
99% specific for Graves’ disease; other autoantibodies (anti-thyroid peroxidase (TPO), 
thyroglobulin) are non-specific and less helpful.4 Perform also baseline full blood count and liver 
function tests; these results will be useful if anti-thyroid drugs (ATDs) are commenced. 
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Thyroiditis—Inflammatory markers (C reactive protein/erythrocyte sedimentation rate) are useful 
if thyroiditis is suspected. 
Goitre—Arrange thyroid ultrasound ahead of secondary care review if a large goitre is identified 
on examination. Further investigation of nodules does not need to be arranged before referring to 
secondary care unless there are specific features suspicious for malignancy (rapidly enlarging 
nodule, cervical lymphadenopathy, hoarseness/voice changes).5 
 
Management 
Offer referral to an endocrinologist for all patients with newly diagnosed hyperthyroidism for 
confirmation of the underlying cause, further investigation as necessary and to recommend a 
management plan. 
For women of childbearing age, discuss and offer contraception until thyrotoxicosis is controlled. 
Prescribe beta blockers for rate control in those with tachycardia. 
Offer to prescribe anti-thyroid drugs (box 3) in patients who have a likely non-transient cause of 
hyperthyroidism and: 
- Free thyroid hormones elevated above the upper limit of the local reference range; and 
- Symptoms uncontrolled despite beta blockers.3 
In elderly patients or those with underlying cardiac disease, there is a high risk of 
decompensation precipitated by thyrotoxicosis and initiation of treatment, and treatment can be 
considered even if symptoms are minimal or if the thyroid hormone levels are not markedly elevated.  
Box start 
Box 3 Starting anti-thyroid drugs (ATDs) in primary care 
• Perform baseline full blood count and liver function tests before initiating ATDs. 
• Explain that there is a risk of agranulocytosis (up to 5 per 1000 patients) and hepatotoxicity (up to 1 
per 250 patients with carbimazole, up to 1 per 37 patients with propylthiouracil) associated with 
ATDs.6 7 
• Provide written information about the need to stop treatment and attend for urgent blood tests if 
fever, sore throat, mouth ulcers, or jaundice develop. 
• ATDs usually reduce symptoms within days. Biochemical euthyroidism is typically achieved after 
3-6 weeks. 
• In Graves’ disease, treatment aims to induce remission and is continued for 12-18 months before 
attempting withdrawal. 
• In toxic adenoma/multinodular goitre, ATDs are used to induce a euthyroid state ahead of 
definitive intervention (radioiodine, thyroidectomy). 
• Before initiation, seek guidance from a local endocrinologist on dosing, monitoring, or other 
aspects, if needed. 
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•  Pregnancy—Propylthiouracil is the agent of choice for patients who are pregnant or planning to 
conceive. Initiation is not usually recommended in primary care. Seek specialist advice in such 
cases. 
Box end 
Reduce symptoms of thyrotoxicosis—Typically, high initial doses of carbimazole, e.g. 30-40 mg 
daily, are introduced where thyroid hormone levels are markedly elevated (fT4 >40 pmol/L), and 
down-titrated depending on biochemical and symptomatic response. Lower doses, e.g. 10-25 mg 
daily can be considered if the thyroid hormone levels are less markedly elevated (fT4 25-40 pmol/L).  
Propylthiouracil is not typically the first line treatment in primary care because of a small risk of 
severe liver injury in 1 in 10,000 patients, but can be considered if there has been a previous history 
of adverse effects with carbimazole, or in women who are currently pregnant or considering 
pregnancy in the near future. Seek specialist advice in such cases. 
Arrange review with repeat thyroid function tests in 2-4 weeks if ATDs have been initiated, or if 
the patient is at high risk of decompensation. Otherwise, monitor thyroid function 4-6 weekly while 
awaiting specialist review.3  
Ongoing treatment (box 4)—If Graves’ disease is confirmed, treatment is continued for 12-18 
months, during which time the underlying autoimmune activity settles in about half of cases. 
Radioactive iodine or thyroidectomy constitute definitive treatment in toxic adenoma/multinodular 
goitre or persistent thyrotoxicosis in Graves’ disease following withdrawal of ATDs. Thyroiditis 
generally requires no specific treatment, but thyroid function tests will be monitored until they 
normalise. 
 Eye symptoms—Discuss thyroid eye disease briefly in all patients in whom Graves’ disease is 
suspected. If features of eye disease are present (grittiness, epiphora, proptosis, lid swelling, visual 
blurring), prescribe simple ocular lubricants (e.g. hypromellose) and arrange early ophthalmology 
referral, preferably to a specialist thyroid eye disease clinic. Graves’ orbitopathy can occur in the 
context of hyper-, hypo-, or euthyroidism, and may precede onset of abnormal thyroid function. 
Various symptom severity scores may aid assessment of Graves’ orbitopathy (e.g. DiaGO, 
CAS/EUGOGO—see box 7).8 9  
Refer urgently if sight threatening complications are suspected: corneal exposure 
(cornea/sclera visible with eyes closed), globe subluxation (restricted eye movements), or optic 
neuropathy (deterioration in visual acuity or colour discrimination). Strongly advise smoking 
cessation if applicable. Evidence supports the use of selenium 100 mcg twice daily, which can be 
purchased over the counter, to slow disease progression and improve quality of life in mild thyroid 
eye disease.10 
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Thyrotoxic crisis (‘thyroid storm’)—Though very rarely seen in primary care, this is a medical 
emergency. Consider the diagnosis if the patient appears acutely unwell, agitated, febrile, or has 
features of heart failure (box 1). The Burch-Wartofsky score (box 7) is a useful assessment tool. If 
suspected, arrange immediate admission for medical assessment. 
Box start 
Box 4 What happens in secondary care 
• In the absence of thyroid stimulating hormone receptor antibodies, thyroid scintigraphy 
(radionuclide uptake scanning) and ultrasound ± colour-flow Doppler may provide useful 
information about aetiology, e.g. toxic adenoma or multinodular goitre.  
• ATDs, radioactive iodine, and/or (sub)total thyroidectomy are the principal approaches to 
management. Choice of approach depends on the underlying aetiology, clinical factors and 
patient preference. 
• Follow-up continues in secondary care until treatment is complete and the patient is stable, i.e. after 
resolution of thyroiditis, one year of remission in Graves’ disease or once thyroid function is 
stable following radioactive iodine or surgery. 
• At discharge, patients receive guidance about ongoing frequency of thyroid function monitoring in 
primary care. 
• Lifelong monitoring in primary care is recommended for patients with Graves’ disease due to the 
risk of future relapse. 
Box end 
Box start 
Box 5 Education into practice 
• How might this article encourage you to adapt your first consultations with patients with a new 
diagnosis of hyperthyroidism? 
• How do you routinely discuss the risks of pregnancy in women of childbearing age who have 
thyrotoxicosis? 
• How comfortable do you feel to start treatment with anti-thyroid drugs as a non-specialist? 
Box end 
Box start 
Box 6 Patient resources 
British Thyroid Foundation: http://www.btf-thyroid.org 
American Thyroid Association: https://www.thyroid.org 
Thyroid Eye Disease Charitable Trust: http://tedct.org.uk 
Guide to anti-thyroid drug therapy, covering risks including agranulocytosis: http://www.btf-
thyroid.org/information/ quick-guides/103-hyperthyroidism-antithyroid-drug-therapy 




Box 7 Resources for clinicians 
Thyroid eye disease assessment tools: 
DiaGO: http://www.btf-thyroid.org/images/documents/S4.pdf 
Modified CAS/EUGOGO: http://www.btf-thyroid.org/images/documents/S3.pdf 
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Box 8 Patient involvement 
Janis Hickey, director of the British Thyroid Foundation, provided guidance regarding the scope and 
content of the article. She has extensive insight into the patient experience at diagnosis and beyond 
through her personal experience as a patient with Graves’ and thyroid eye disease, and many years of 
patient advocacy. She contributed perspectives on important areas to highlight for a generalist 
audience, based on aspects of initial management that impact the patient experience. 
Box end 
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